[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343114-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343114-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","genomic-profiles-and-clinical-presentation-of-chordoma","Genomic profiles and clinical presentation of chordoma","","Chordoma is a rare bone cancer with variable clinical outcomes. The study recruited 184 sporadic chordoma patients from the US and Canada and compiled clinical and treatment data. The average age at diagnosis was 45.5 years, with tumor sites distributed across clivus, spinal, and sacral regions. Most patients received surgery, and among a tumor subset, omics analyses produced targeted panel sequencing and SNP array genotyping, identifying recurrent driver alterations and links between 14q/18p deletions and persistent disease, highlighting genomic heterogeneity by location.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/genomic-profiles-and-clinical-presentation-of-chordoma/343114/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/genomic-profiles-and-clinical-presentation-of-chordoma/343114.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical features and treatment patterns were reported for the chordoma patients?","Question",{"text":63,"@type":64},"The cohort included 184 sporadic patients, with an average diagnosis age of 45.5 years. Most patients received surgery as the primary treatment, and many also received additional treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What genomic approaches were used in the tumor subset?",{"text":68,"@type":64},"For a subset of patients with tumor materials (N=70), targeted panel sequencing and SNP array genotyping were performed as part of omics analyses.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genetic alterations were most recurrent and how were they linked to disease persistence?",{"text":72,"@type":64},"The most recurrent somatic driver mutation involved PIK3CA, and amplification of the 6q27 region was detected in some patients. After adjustment, somatic deletions of 14q and 18p were associated with higher likelihood of persistent chordoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343114,1791164474,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Koka etal. Acta Neuropathologica  \nActa Neuropathologica Communications (2024) 12:129  \n[https://doi.org/10.1186/s40478-024-01833-9](https://doi.org/10.1186/s40478-024-01833-9 Communications)[ Communications](https://doi.org/10.1186/s40478-024-01833-9 Communications)  \n RESEARCH Open Access  \nGenomic profiles and clinical presentation   of chordoma  \nHela Koka1, Weiyin Zhou1,2, Mary L. McMaster 1, Jiwei Bai3, Wen Luo1,2, Alyssa Klein1, Tongwu Zhang1,  \nXing Hua1,2, Xin Li1,2, Difei Wang1,2, Yujia Xiong4, Kristine Jones1,2, Aurelie Vogt1,2, Belynda Hicks1,2, Dilys Parry1^, Alisa M. Goldstein 1† and Xiaohong R. Yang 1*†  \nAbstract  \nChordoma is a rare bone cancer with variable clinical outcomes. Here, we recruited 184 sporadic chordoma patients from the US and Canada and collected their clinical and treatment data. The average age at diagnosis was 45.5 years (Range 5–78) and the chordoma site distribution was 49. 2% clivus, 26. 2% spinal, and 24. 0% sacral. Most patients (97 . 5%) received surgery as the primary treatment, among whom 85. 3% also received additional treatment. Except for the most prevalent cancers like prostate, lung, breast, and skin cancer, there was no discernible enrichment for any specific cancer type among patients or their family members. Among a subset of patients (N = 70) with tumor materials, we conducted omics analyses and obtained targeted panel sequencing and SNP array genotyping data for 51 and 49 patients, respectively. The most recurrent somatic driver mutations included PIK3CA (12%), followed by chromatin remodeling genes PBRM1 and SETD2 . Amplification of the 6q27 region, containing the chordoma susceptibility gene TBXT, was detected in eight patients (16 . 3%) . Clival patients appeared to be less likely to carry driver gene mutations, chromosome arm level deletion events (e. g., 5p, 5p, and 9p), or 6q27 amplification compared to sacral patients. After adjusting for age, sex, tumor site, and additional treatment, patients with somatic deletions of 14q (OR = 13 . 73, 95% CI 1.96–96. 02, P = 0 . 008) and 18p (OR = 13 . 68, 95% CI 1.77–105. 89, P = 0 . 012) were more likely to have persistent chordoma. The study highlights genomic heterogeneity in chordoma, potentially linked to location and clinical progression.  \nKeywords Chordoma, Chordoma sites, Treatment, Genomic landscape, Clinical outcome  \n\n| †Alisa M. Goldstein and Xiaohong R. Yang are Co-senior author. |\n| --- |\n| ^Dilys Parry: Deceased. |\n\n*Correspondence: Xiaohong R. Yang[royang@mail.nih.gov](royang@mail.nih.gov)  \n1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA  \n2 Cancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA  \n3 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China  \n4 Department of Pathology, West China Hospital, Sichuan University, Chengdu, China  \nIntroduction  \nChordoma is a rare, slow-growing bone tumor (\u003C 1 per 100,000) which is believed to originate from notochordal remnants that persist along the axial skeleton into adulthood. The usual sites of origin include the skull-base, mobile spine, and sacrum/coccyx. The incidence of chordoma increases with age and is very rare in young patients, particularly in the first decade of life [1]. Although chordomas are considered slow-growing, local recurrence is common.  \nSurgery is the mainstay of treatment for chordoma with radiation therapy as an optional adjuvant treatment, often depending on the location and extent of the tumor. Proton radiation therapy is regularly considered the best  \nThis is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in ","cbCairEQYYa2e6d0","https://ap.wps.com/l/cbCairEQYYa2e6d0","pdf",1285526,"English","# Abstract\n# Introduction\n## Disease background and treatment\n## Need for genomic stratification\n## Prior genomic findings and study gap","[{\"question\":\"What clinical features and treatment patterns were reported for the chordoma patients?\",\"answer\":\"The cohort included 184 sporadic patients, with an average diagnosis age of 45.5 years. Most patients received surgery as the primary treatment, and many also received additional treatment.\"},{\"question\":\"What genomic approaches were used in the tumor subset?\",\"answer\":\"For a subset of patients with tumor materials (N=70), targeted panel sequencing and SNP array genotyping were performed as part of omics analyses.\"},{\"question\":\"Which genetic alterations were most recurrent and how were they linked to disease persistence?\",\"answer\":\"The most recurrent somatic driver mutation involved PIK3CA, and amplification of the 6q27 region was detected in some patients. After adjustment, somatic deletions of 14q and 18p were associated with higher likelihood of persistent chordoma.\"}]","Genomic profiles and clinical presentation of chordoma | PDF",1790049953,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b0f69d1a2606e7ea5375ffa331bd884.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abb530e95d68c0548ddb7aa821df36b3.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff4053624c23fc2ab9aa6cf8246a7277.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92e357718f88f0d348db49b2e9056e6d.webp",980,1301]